With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines .

A visual that features the new Welcome to Memphis logo. Elizabeth Berglund was the graphic designer Welcome to Memphis worked ...

Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They ...

"The first-of-its-kind campaign, which sparked a global phenomenon by swapping iconic Coca-Cola logos for personalised names, ...

Boehringer plans to use One Medicine to boost its development of new medicines, the company said in a March 11 release, by linking data across functions and improving trial efficiency and ...

Top 20 biopharma goes live with Veeva Development Cloud to speed the delivery of treatments for currently incurable diseases "Together with Veeva, Boehringer has advanced its approach to clinical ...

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 ...

Cognizant (Nasdaq: CTSH) and Boehringer Ingelheim announced today the go-live of an end-to-end technology platform powered by the Veeva Development Cloud, designed to accelerate the global ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

"We are pleased to achieve this program milestone in our collaboration with Boehringer Ingelheim," said Gagan Syal, Head of Life Sciences, EMEA & APAC, at Cognizant. "With this new system ...

A research led by Sergio P. Acebrón, Researcher Ikerbasque at the UPV/EHU, develops a key tool to visualize the immune response to abnormal DNA, opening new avenues for the treatment of diseases.